Illumina, Inc. (NASDAQ:ILMN) has been given an average rating of “Hold” by the twenty-five ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $203.39.

A number of analysts recently weighed in on ILMN shares. Deutsche Bank AG set a $175.00 price target on shares of Illumina and gave the company a “hold” rating in a research report on Friday, July 28th. Citigroup Inc. increased their price target on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, October 25th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and increased their price target for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Robert W. Baird upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and increased their price target for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Finally, Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target on the stock in a research report on Friday, October 27th.

In related news, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Oene Mark Van sold 9,729 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the transaction, the senior vice president now directly owns 24,908 shares of the company’s stock, valued at $5,263,807.64. The disclosure for this sale can be found here. Insiders sold 172,446 shares of company stock valued at $35,486,114 over the last three months. 1.60% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in ILMN. Dimensional Fund Advisors LP boosted its position in Illumina by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 264,925 shares of the life sciences company’s stock worth $45,211,000 after purchasing an additional 9,017 shares during the period. KCG Holdings Inc. bought a new position in Illumina during the first quarter worth $290,000. Tudor Investment Corp ET AL bought a new position in Illumina during the first quarter worth $289,000. NN Investment Partners Holdings N.V. boosted its position in Illumina by 11.3% during the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the period. Finally, State of Alaska Department of Revenue bought a new position in Illumina during the second quarter worth $345,000. 92.70% of the stock is owned by hedge funds and other institutional investors.

Shares of Illumina (NASDAQ ILMN) traded up $0.51 during midday trading on Monday, hitting $209.02. 545,558 shares of the stock traded hands, compared to its average volume of 716,627. The company has a market cap of $30,520.00, a price-to-earnings ratio of 60.25, a PEG ratio of 3.40 and a beta of 0.74. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a one year low of $119.37 and a one year high of $214.50.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. equities research analysts expect that Illumina will post 3.75 EPS for the current year.

WARNING: “Illumina, Inc. (ILMN) Receives $203.39 Consensus Price Target from Analysts” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/illumina-inc-ilmn-receives-203-39-consensus-price-target-from-analysts.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.